Carole Mitnick, ScD on the politics of medical knowledge production and its impact on TB treatment standards, with discussant Mercedes Becerra, ScD.
Carole Diane Mitnick's , ScD Associate Professor of Global Health and Social Medicine, research centers on the improvement of clinical management and programmatic policy for tuberculosis and multidrug-resistant tuberculosis (MDR-TB) globally. Dr. Mitnick is a founding investigator of a movement to conduct randomized controlled clinical trials to improve treatment of drug-resistant TB (RESIST-TB). Dr. Mitnick’s work also includes applying marginal structural modeling to MDR-TB treatment data to assess the effect on outcomes of different types of therapy in observational studies. Dr. Mitnick is the principal investigator of an NIAID grant to plan a Phase II clinical trial examining the potential of high-dose rifampin to shorten standard TB therapy. Her research questions are strongly influenced by the mission of Partners In Health, with which Dr. Mitnick has worked since 1996: she strives to conduct research that will effect changes in global policy to ensure the highest standard of care and best treatment outcomes for patients suffering from all forms of tuberculosis, regardless of where they live.
Mercedes Corina Becerra's, ScD Professor of Global Health and Social Medicine, research focuses on the treatment and epidemiology of tuberculosis. She studies the burden of tuberculosis in the child and adult household contacts of tuberculosis patients. She also studies strategies to improve tuberculosis screening and treatment in children and high-risk households.
ORGANIZER: Harvard Medical School - Global Health and Social Medicine